# US 2019/0375844 A1 · Antibodies and polypeptides directed against cd127

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375844 A1
- Document ID: US20190375844A1
- Status: Published application
- Kind: A1
- Application number: 16/467,284
- Filed: 2017-12-07
- Published: 2019-12-12
- Earliest claimed: 2016-12-09
- Assignees: Ose Immunotherapeutics
- Applicants: Ose Immunotherapeutics
- Inventors: Nicolas POIRIER; Caroline MARY; Bernard VANHOVE; Virginie THEPENIER
- Web page: https://patentgrep.com/patent/US20190375844A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/244: {Interleukins [IL]}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention is in the field of antibodies useful in therapeutic and diagnostics applications targeting CD127, the alpha chain of the IL7 receptor, and provides in particular humanized monoclonal antibodies against CD127, particularly human CD127, therapeutic uses thereof, and diagnostics applications.

## Claims

### Claim 1

An antibody or an antigen-binding fragment thereof, which specifically binds to CD127, in particular to human CD127, comprising:
an antibody light chain comprising or an antibody light chain variable domain consisting of a sequence selected from the group consisting of SEQ ID No: 9; SEQ ID No: 10; SEQ ID No: 11; SEQ ID No: 12; in particular SEQ ID No: 12; and
an antibody heavy chain variable domain comprising the three CDRs consisting of the sequences set forth in SEQ ID No: 1, SEQ ID No: 2, and SEQ ID No: 3, in particular an antibody heavy chain variable domain consisting of the sequence set forth in SEQ ID No: 7.

### Claim 2 (depends on 1)

The antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a humanized monoclonal antibody, in particular wherein the antibody light chain constant domain is derived from a human kappa light chain constant domain, in particular wherein the light chain constant domain consists of the sequence of SEQ ID No:27 or 28, and wherein the antibody heavy chain constant domain is derived from a human IgG1, IgG2, IgG3, or IgG4 heavy chain constant domain, in particular from a human IgG4 heavy chain constant domain, in particular wherein the antibody heavy chain constant domain consists of the sequence with SEQ ID No:26.

### Claim 3 (depends on 1, 2)

The antibody or antigen-binding fragment thereof according to claim 1 or 2, wherein the antibody light chain comprises or the antibody light chain variable domain consists of SEQ ID No: 12 and wherein the antibody heavy chain variable domain consists of SEQ ID No: 7.

### Claim 4 (depends on 1, 2, 3)

The antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, which is an antagonist of IL-7R signalling induced by IL-7 and which does not induce the activation of the phosphatidylinositol 3-kinase and/or of the ERK signalling pathway.

### Claim 5 (depends on 1, 2, 3, 4)

The antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, which recognizes an epitope comprising a sequence taken from the 2b site of CD127 and/or disrupts the binding of CD127 to the γc common chain of cytokine receptors, in particular which recognized at least the third beta sheet of the site 2b of CD127.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, which does not induce the internalization of CD127 and/or inhibits IL7-induced internalization of CD127.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, which does not increase the maturation of dendritic cells induced by TSLP.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, which has a long-lasting effect and/or a fast effect, in particular which has a fast local effect.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The antibody or antigen-binding fragment thereof according to any one of claims 1 to 8, which specifically binds to human CD127 with an affinity constant KD lower than 5E-9 M, as may be determined by biosensor analysis.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A combination of isolated nucleic acid molecules encoding an antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, in particular a first isolated nucleic acid molecule comprising or consisting of a sequence selected from the group consisting of SEQ ID No: 15, SEQ ID No: 16, SEQ ID No: 17 and SEQ ID No: 18; and a second isolated nucleic acid molecule comprising or consisting of the sequence of SEQ ID No: 13.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9 and/or the combination of isolated nucleic acid molecules according to claim 10, and a pharmaceutical vehicle.

### Claim 12 (depends on 11)

The pharmaceutical composition according to claim 11, which is suitable for local administration, in particular for local subcutaneous, enteric or oral administration, more particularly for delivery to the colon.

### Claim 13 (depends on 11, 12)

A kit comprising a pharmaceutical composition of claim 11 or claim 12 and a delivery device suitable for local administration, in particular a subcutaneous, enteric or oral delivery device, more particularly said device comprising a pre-filled syringe or a needle-free device.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, or the combination of isolated nucleic acid molecules according to claim 10, or the pharmaceutical composition according to claim 11 or 12, or the kit of claim 13, for use as a medicament.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, or the combination of isolated nucleic acid molecules according to claim 10, or the pharmaceutical composition according to claim 11 or 12, or the kit of claim 13, for use according to claim 14 in the prevention or treatment of organ or tissue transplant rejection or of a disease selected from the group consisting of autoimmune diseases, particularly rheumatoid arthritis, systemic sclerosis, multiple sclerosis, type I diabetes, autoimmune thyroiditis, systemic lupus erythematosus, primary Sjögren syndrome, and inflammatory diseases, particularly inflammatory bowel disease (IBD), more particularly Crohn's disease and ulcerative colitis and encephalomyelitis and allergic diseases and cancer diseases and diseases related to transplantation and respiratory diseases.

### Claim 16

A method of selecting a compound from the group consisting of an antibody, an antigen-binding fragment thereof or an antibody mimetic molecule and comprising or consisting of at least one of the following steps:
i. testing the binding capacity of the compound to CD127, in particular to human CD127, in particular to an epitope sequence from domain D1 and/or from site 2b of domain D2 of human CD127;
ii. testing the inhibition of IL7-R signalling induced by IL7, in particular STAT-5 phosphorylation, in presence of the compound;
iii. testing the activation of the phosphatidylinositol 3-kinase in presence of the compound;
iv. testing the activation of the ERK signalling pathway in presence of the compound;
v. testing the binding capacity of the compound to at least the third beta sheet of the site 2b of CD127, in particular to human CD127;
and optionally further comprising at least one of the following steps:
vi. testing the binding of CD127 to the γc common chain of cytokine receptors in presence of the compound;
vii. testing the internalization of CD127 and/or IL7-induced internalization of CD127 in presence of the compound;
viii. testing the maturation of dendritic cells induced by TSLP in presence of the compound;
particularly wherein the compound which specifically binds to CD127 is an antagonist of IL-7R signalling induced by IL-7 and which does not induce the activation of the phosphatidylinositol 3-kinase and/or the ERK signalling pathway is selected.
